Anika Therapeutics Inc (ANIK) - Cash Flow Conversion Efficiency

Latest as of June 2026: -0.005x

Based on the latest financial reports, Anika Therapeutics Inc (ANIK) has a cash flow conversion efficiency ratio of -0.005x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-684.00K) by net assets ($137.28 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see ANIK company net worth for the company's overall valuation and market capitalisation.

Anika Therapeutics Inc - Cash Flow Conversion Efficiency Trend (1993–2025)

This chart illustrates how Anika Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Anika Therapeutics Inc Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Anika Therapeutics Inc ranked by their cash flow conversion efficiency. Explore Anika Therapeutics Inc cash earnings quality to measure how well operating cash flow supports reported net income.

Company Cash Flow Conversion Efficiency
WONIK Materials Co.Ltd
KQ:104830
0.029x
Southeast Cement Co Ltd
TW:1110
0.009x
J.Jill Inc
NYSE:JILL
0.014x
Cloud Live Technology Group Co Ltd
SHE:002306
-0.026x
Nivika Fastigheter AB Series B
ST:NIVI-B
0.003x
Ouro Fino Saúde Animal Participações S.A
SA:OFSA3
0.166x
Transcontinental Inc
TO:TCL-A
-0.095x
Tudor Gold Corp
V:TUD
-0.003x

Annual Cash Flow Conversion Efficiency for Anika Therapeutics Inc (1993–2025)

The table below shows the annual cash flow conversion efficiency of Anika Therapeutics Inc from 1993 to 2025. View ANIK share price today for real-time trading data and today's change.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 $143.47 Million $11.19 Million 0.078x +122.26%
2024-12-31 $153.99 Million $5.40 Million 0.035x +516.54%
2023-12-31 $212.26 Million $-1.79 Million -0.008x -154.56%
2022-12-31 $285.56 Million $4.41 Million 0.015x -47.21%
2021-12-31 $287.08 Million $8.40 Million 0.029x -39.02%
2020-12-31 $272.40 Million $13.06 Million 0.048x -62.62%
2019-12-31 $288.38 Million $37.01 Million 0.128x -3.12%
2018-12-31 $263.61 Million $34.92 Million 0.132x -14.48%
2017-12-31 $263.49 Million $40.81 Million 0.155x +44.97%
2016-12-31 $222.77 Million $23.80 Million 0.107x -42.33%
2015-12-31 $210.85 Million $39.06 Million 0.185x -17.46%
2014-12-31 $178.10 Million $39.98 Million 0.224x +20.99%
2013-12-31 $135.63 Million $25.16 Million 0.186x +91.58%
2012-12-31 $108.93 Million $10.55 Million 0.097x -9.79%
2011-12-31 $94.76 Million $10.17 Million 0.107x +16.45%
2010-12-31 $85.19 Million $7.85 Million 0.092x +144.70%
2009-12-31 $82.14 Million $3.09 Million 0.038x -32.82%
2008-12-31 $60.76 Million $3.41 Million 0.056x -31.39%
2007-12-31 $54.96 Million $4.49 Million 0.082x +85.81%
2006-12-31 $45.49 Million $2.00 Million 0.044x -74.16%
2005-12-31 $37.89 Million $6.45 Million 0.170x -78.30%
2004-12-31 $30.36 Million $23.82 Million 0.785x +601.34%
2003-12-31 $17.98 Million $2.01 Million 0.112x +474.96%
2002-12-31 $17.06 Million $332.03K 0.019x +109.07%
2001-12-31 $20.10 Million $-4.31 Million -0.215x -204.37%
2000-12-31 $26.71 Million $-1.88 Million -0.071x -326.50%
1999-12-31 $25.70 Million $800.00K 0.031x -72.63%
1998-12-31 $29.90 Million $3.40 Million 0.114x +14.59%
1997-12-31 $26.20 Million $2.60 Million 0.099x +145.11%
1996-12-31 $5.00 Million $-1.10 Million -0.220x +24.94%
1995-12-31 $5.80 Million $-1.70 Million -0.293x +34.05%
1994-12-31 $5.40 Million $-2.40 Million -0.444x -495.56%
1993-12-31 $6.70 Million $-500.00K -0.075x --

About Anika Therapeutics Inc

NASDAQ:ANIK USA Drug Manufacturers - Specialty & Generic
Market Cap
$278.50 Million
Market Cap Rank
#15277 Global
#3602 in USA
Share Price
$20.81
Change (1 day)
-1.05%
52-Week Range
$9.00 - $22.03
All Time High
$73.36
About

Anika Therapeutics, Inc., a joint preservation company, focuses on early intervention orthopedics in the United States, Europe, and internationally. The company offers osteoarthritis (OA) pain management products and services, such as Monovisc and Orthovisc, which are single- and multi-injection, HA viscosupplement products indicated for pain relief from OA conditions, as well as Cingal, a non-op… Read more